ER+ve breast cancers are typically treated with endocrine therapies, such as tamoxifen, a selective estrogen receptor modulator (SERM), while HER2+ cancers receive anti-HER2 therapies [4]. This evidence concerns the gene ERBB2 and breast cancer.